Bank Of America Corp Selecta Biosciences Inc Transaction History

Bank Of America Corp

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$0.62 - $0.85 $96,579 - $132,407	-155,774 Reduced 81.19%	36,096 $30,000
Q4 2023 Feb 14, 2024	BUY	$0.67 - $1.35 $84,231 - $169,720	125,719 Added 190.05%	191,870 $132,000
Q2 2023 Aug 14, 2023	SELL	$1.04 - $1.4 $32,878 - $44,259	-31,614 Reduced 32.34%	66,151 $74,000
Q1 2023 May 12, 2023	BUY	$1.15 - $1.89 $55,872 - $91,825	48,585 Added 98.79%	97,765 $135,000
Q4 2022 Feb 10, 2023	SELL	$0.96 - $1.6 $29,430 - $49,051	-30,657 Reduced 38.4%	49,180 $55,000
Q3 2022 Nov 14, 2022	BUY	$1.33 - $2.6 $24,518 - $47,931	18,435 Added 30.02%	79,837 $131,000
Q2 2022 Aug 12, 2022	SELL	$0.67 - $1.4 $21,723 - $45,392	-32,423 Reduced 34.56%	61,402 $80,000
Q1 2022 May 16, 2022	SELL	$1.23 - $3.31 $59,657 - $160,541	-48,502 Reduced 34.08%	93,825 $115,000
Q4 2021 Feb 08, 2022	BUY	$2.89 - $4.43 $366,963 - $562,508	126,977 Added 827.21%	142,327 $464,000
Q3 2021 Nov 15, 2021	BUY	$3.36 - $4.62 $13,581 - $18,674	4,042 Added 35.74%	15,350 $64,000
Q2 2021 Sep 13, 2021	BUY	$2.82 - $5.01 $31,888 - $56,653	11,308 New	11,308 $47,000

4.67M

Ticker SELB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 152,712,992
Market Cap $128M
Description
Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's lead therapeutic gene therapy program is SEL-302 that is in preclinical stage to improve the treatment of methylmalonic acidemia. I...

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

Stay updated on Bank Of America Corp with notifications on news.